AbbVie Presents Results of Imbruvica (ibrutinib) + Venclexta/Venclyxto in P-III GLOW Study as 1L Treatment for CLL or SLL at EHA 2021

June 14, 2021 Auto Bot AbbVie, Clinical Trials, EHA 2021, Imbruvica, P-III, Venclexta 0

Shots:

  • The P-III GLOW study evaluates Imbruvica + Venclexta/Venclyxto (I+V) vs chlorambucil + obinutuzumab (C+O) in 211 patients in a ratio (1:1) aged ≥65yrs. with CLL/SLL
  • The study met its 1EPs of PFS as assessed by IRC & showed a 78% reduction in risk of disease progression or death, mPFS (not reached vs 21mos.) & safety profile of the combination was consistent with the safety profile of monothx. & tolerability profiles were consistent with CLL treatment in a patient population
  • The 2EPs includes uMRD (51.9% vs 17.1%) @3mos., PB uMRD (49% vs 12%) @12mos., CR rate (38.7% vs 11.4%), ORR was not different b/w treated groups, time to subsequent therapy was longer for I+V

Click here to­ read full press release/ article | Ref: Abbvie | Image: Pharma Live

The post AbbVie Presents Results of Imbruvica (ibrutinib) + Venclexta/Venclyxto in P-III GLOW Study as 1L Treatment for CLL or SLL at EHA 2021 first appeared on PharmaShots.